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To the Editor:
IL10 is an immunoregulatory cytokine that has a central role in
the maintenance of intestinal mucosal homeostasis and preven-
tion of colitis [1]. Loss-of-function mutations in IL10, IL10RA,
or IL10RB cause severe intestinal inflammation and perianal
disease that presents in the first months of life and is refractory
to conventional immunosuppressive medications such as ste-
roids, anti-TNFα antibodies, and immunomodulators [2]. The
definitive treatment for IL10R deficiency is an allogeneic
hematopoietic stem cell transplantation (HSCT) to reconstitute
IL10 signaling, if a suitable donor is available. Unfortunately,
the clinical condition of many of these patients is not amenable
to transplant at the time of their diagnosis. As such, a therapeu-
tic bridge is needed to prepare them for transplant.
We have recently shown that IL1β is highly upregulated in
IL10R deficiency [3], and blocking IL1 attenuated colitis in an
IL10R-deficient mouse model. Thus, we elected to treat two
patients with medical-refractory severe inflammatory bowel
disease (IBD) secondary to IL10R deficiency with anakinra,
an IL1 receptor antagonist. In both cases, high dose anakinra
therapy (10–12 mg/kg/day) led to marked clinical, endoscop-
ic, and histological improvement within a few weeks [3]. To
date, this is the first report of treatment that suppressed the
hyperactive immune response in the gut of these patients.
Herein, we present additional information on one of these
patients, a 28-year-old IL10R-deficient patient with a history
of severe infantile-onset IBD, whose condition improved sig-
nificantly after anakinra treatment. This patient initially pre-
sented with bloody diarrhea and was diagnosed with IBD at
6 months of age. He underwent a subtotal colectomy with end
ileostomy at age 7 years and developed enterocutaneous fis-
tulae at the age of 18. At age 23, a large B cell lymphoma was
discovered and he received R-CHOP chemotherapy. An
ileoscopy at age 28 demonstrated severe ileitis (Fig. 1a) and
examination of the abdominal wall revealed multiple
enterocutaneous fistulae. After the confirmation of an
IL10RA loss-of-function mutation in this patient, he was
started on anakinra. During the initial 2 weeks of treatment
dose escalated to 12 mg/kg/day subcutaneously. At 4 weeks, a
repeat ileoscopy showed he had a substantial improvement in
his mucosal inflammation (Fig. 1a). The patient also experi-
enced a significant decrease in his ileostomy output and
marked weight gain within a few months. There were no sig-
nificant changes in his serum inflammatory markers. Overall,
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the patient was treated with anakinra for 6 months without any
significant side effects and is currently being prepared for an
allogenic HSCT [3].
To further understand the mechanism of anakinra treatment
in the IL10R-deficient patient, we compared the frequency of
IL22-producing lymphocytes in lamina propria mononuclear
Fig. 1 Anakinra treatment induces increased IL22 production in the terminal ileum and peripheral blood of IL10R-deficient patient
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cells (LPMC) isolated from his terminal ileum biopsy samples
taken pre- and post-anakinra treatment. IL22-producing lym-
phocytes were our primary targets because of their known role
in healing of intestinal inflammation. In the lineage negative
compartment, we did not find IL22-producing innate lymphoid
cell group 3 (ILC3). However, the frequency of IL22-producing
lymphocytes among lineage (+) CD45 (+) LPMC greatly in-
creased from 2.17% pre-anakinra to 50.9% post-anakinra
(Fig. 1b). Analysis of an additional ileal biopsy 3 months later
demonstrated that the number further increased to 53.9% among
lineage (+) CD45 (+) LPMC (Fig. 1b). Furthermore, H&E stain-
ing of this additional biopsy showed resolution of the severely
inflamed ileal region 5 cm above the ileostomy (Fig. 1a). The
remaining 5 cm with associated enterocutaous fistulae remained
inflamed. In addition, asmentioned in our recent publication, the
inflammatory changes in the skin adjacent to the patient’s
ileostomy and fistulae also resolved. Overall, our data suggest
that anakinra-induced IL22 production may have a role in mu-
cosal healing in this IL10R-deficient patient.
During a recent clinical trial among hidradenitis suppurativa
patients, Vassiliki et al. observed significantly increased pro-
duction of IL22 by peripheral blood mononuclear cells
(PBMC) following anakinra therapy and concluded that the
increased IL22 might contribute to an improved epithelial cell
defense [4]. Based on these observations, we decided to assess
IL22 production in the LPMC compartment of our sporadic
adult Crohn’s disease population (Supplementary Table. 1).
We detected a trend towards reduction of the IL22-producing
lymphocytes (p = 0.07) among Lineage (+) CD45 (+) LPMC in
the inflamed tissue (2.89%, n = 9) compared to unaffected
tissue (5.75%, n = 3) (Fig. 1c). This result complements another
report that IL22-producing CD4+ cells were depleted in active
inflamed lesions of ulcerative colitis (UC) patients [5].
The deficiency of IL22-producing lymphocytes in the in-
flamed gut and the fact that its recovery coincided with im-
proved intestinal inflammation suggest a protective role of this
population in the gastrointestinal tract and that it might serve as
a surrogate marker of mucosal healing. IL22 is a member of the
IL10 family of cytokines. It directly binds to the heterodimeric
receptor IL22Rα1-IL10Rβ on non-hematopoietic cells, espe-
cially on epithelial cells. The binding of IL22 promotes epithe-
lial cell proliferation; secretion of antimicrobial peptides such as
RegIIIβ, RegIIIγ, S108a, and S109a; and mucus production as
well as fucosylation. Specifically, IL22 stimulation leads to the
activation of signal transducer and activator of transcription 3
(STAT3) in epithelial cells, which contributes to tissue repair
after injury. Finally, it is important to mention that this patient is
an IL10RA mutation and his IL10RB is intact. This guarantees
the responsiveness of epithelial cell to the increased IL22 sig-
naling. Response to anakinra in IL10RB-deficient patients
might be less effective but warrants further evaluation.
We subsequently assessed whether the frequency of circu-
lating IL22-producing lymphocytes was altered in our IL10R-
deficient patient, when compared to a Crohn’s disease cohort
and normal controls. Indeed, we observed a significant increase
in blood-borne TH22 and TH17 cells, both single producers
and IL22/IFNγ, IL17A/IFNγ double producers, in the patient,
as well as in Crohn’s disease subjects (Fig. 1d and
Supplementary Fig. 1). It is important to note that the IL10R-
deficient patient was analyzed after starting anakinra therapy,
which we know decreased mucosal IL17 in both treated pa-
tients and might also influence circulating TH17 cells [3].
In conclusion, we present a case of a patient with severe
IBD due to an IL10RAmutation who demonstrated a dramatic
response to anakinra therapy. This intervention led to mucosal
healing accompanied by increased frequency of IL22-
producing lymphocytes in the lamina propria of the terminal
ileum. The increase in IL22, which promoted tissue repair,
might have had an important role in the recovery of this pa-
tient and suggests an additional important mechanistic mode
of action of anakinra in the gut.
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